mulezscript

Listening to the very interesting Engineering Armageddon episode I want to explain the problem with challenge trials that wasn't addressed in the episode.

My understanding comes from listening since the beginning of the pandemic to This Week in Virology podcast which has been spot on during the pandemic.

The main problem:

Having only young, low-risk participants in the trial will not prove the much needed efficacy in the risk groups. We want to know it's safe and effective for the high risk groups so you must have them on the trial.